培美曲塞联合奥沙利铂治疗晚期食管癌疗效观察

目的观察培美曲塞联合奥沙利铂治疗晚期食管癌的疗效和毒刮反应。方法将66例晚期食管癌患者随机分为两组。治疗组给予培美曲塞500mg／m^2静滴，第1天；奥沙利铂120mg／m^2静滴，第1天，21d为一周期。对照组给予5-氟脲嘧啶500mg／m2静滴，第1—5天；亚叶酸钙0．2g静滴，第1-5天；顺铂80mg／m^2静滴，分3天，21d为一周期。结果治疗组总缓解率为68．8％，对照组总缓解率为44．1％，两组比较有统计学意义（P=0．044）。治疗组自细胞减少的发生率低于对照组，但差异无统计学意义（P〉0．05）；治疗组恶心、呕吐和腹泻发生率显著低于对照组（P均〈0．05），神经毒性的发生率显著高于对照组（P〈0．05或〈0．01）。结论奥沙利铂联合培美曲塞治疗晚期食管癌安全、有效率高，毒性反应可以耐受。

Clinical observation of patients with advanced esophageal caner treated with pemetrexed and oxaliplatin

Objective To evaluate the efficacy and the side effects of the regimen of pemetrexed combined with oxaliplatin in the treatment of advanced esophageal cancer. Methods Sixty-six patients with advanced esophageal cancer were enrolled and randomly divided into treatment group and control group. Treatment group:pemerexed 500mg/m2, d1;oxaliplatin 120 mg/m2, d1; with 21 days one cycle.Control group:5-Fu 500mg/m2, d1-5; CF 0.2, d1-5; DDP 80mg/m2, divided into 3 days; with 21 days one cycle. Results The CR rate of treatment group was 6.3% and RR was 68.8%, while 2.9% and 44.1% respectively in control group. Compared with control group, the CR rate of treatment group had no significant difference(P＞0.05); while RR had significant difference(P＝0.044). Compared with control group, the treatment group's incidence of leukopenia(P＞0.05), nausea and vomitting (P＝0.024)and diarrhea(P＝0.032)were lower, while the incidence of neuropathy(P＝0.000) was higher. Conclusions It is safe and effective to treat patients with advanced esophageal cancer with pemetrexed and oxaliplatin